利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

289 条记录 (耗时 0.031 秒)

    Solid phase carrier, ligand-bound solid phase carrier, method for detecting or separating target substance, and method for producing solid phase carrier
    5.
    发明授权
    Solid phase carrier, ligand-bound solid phase carrier, method for detecting or separating target substance, and method for producing solid phase carrier 有权

    公开(公告)号：US11125747B2

    公开(公告)日：2021-09-21

    申请号：US15509684

    申请日：2015-09-07

    申请人： JSR CORPORATION ,  JSR Life Sciences Corporation

    发明人： Yuuichi Ueya

    IPC分类号： G01N33/543 ,  G01N33/547 ,  C08F293/00 ,  C08F257/02 ,  C08L43/02

    摘要： Provided is a solid phase carrier which has high water dispersibility, allows facilitated binding of a ligand to a reactive functional group, and exhibits suppressed non-specific adsorption, and with which, in the case of using the solid phase carrier by having a ligand bound thereto, for example, detection of a target substance can be carried out with high sensitivity and low noise. Disclosed is a solid phase carrier having bound thereto a polymer including a structural unit represented by the following Formula (1) and a structural unit represented by the following Formula (2): wherein in Formula (1), R1 represents a hydrogen atom or a methyl group; and
    R2 represents an organic group having a zwitterionic structure, in Formula (2),
    R3 represents a hydrogen atom or a methyl group
    R4 represents —(C═O)—O—*, —(C═O)—NR6—* (wherein R6 represents a hydrogen atom or a methyl group; and the symbol * represents a position of bonding to R5 in Formula (2)), or a phenylene group;
    in a case in which R4 represents —(C═O)—O—*, R5 represents a hydrogen atom, or an organic group having a reactive functional group, and in a case in which R4 represents —(C═O)—NR6—* or a phenylene group, R5 represents an organic group having a reactive functional group,
    provided that R5 is not an organic group having a zwitterionic structure.

    METHOD FOR DIAGNOSING AND TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER
    6.
    发明申请
    METHOD FOR DIAGNOSING AND TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER 审中-公开

    公开(公告)号：US20200064356A1

    公开(公告)日：2020-02-27

    申请号：US16543741

    申请日：2019-08-19

    申请人： EpicGenetics, Inc.

    发明人： Bruce S. GILLIS

    IPC分类号： G01N33/68 ,  G01N33/547

    摘要： The invention provides methods and compositions for treating attention-deficit/hyperactivity disorder (ADHD) in an individual. The methods provided herein entail administering a composition comprising an isolated Mycobacterium or antigenic fragments derived therefrom. Also provided herein are methods for assessing alleviation of symptoms and/or alteration of immune system functioning following administration of a composition comprising an isolated Mycobacterium or antigenic fragments derived therefrom.

    SPR-based dual-binding assay for the functional analysis of multispecific molecules
    7.
    发明申请
    SPR-based dual-binding assay for the functional analysis of multispecific molecules 审中-公开

    公开(公告)号：US20190317086A1

    公开(公告)日：2019-10-17

    申请号：US16366825

    申请日：2019-03-27

    申请人： Hoffmann-La Roche Inc.

    发明人： Christian Gassner ,  Wolfgang Meschendoerfer ,  Joerg Moelleken

    IPC分类号： G01N33/543 ,  G01N33/547 ,  G01N33/557 ,  G01N33/68 ,  C07K16/46

    摘要： Herein is reported a method for determining the binding of an antibody, which comprises a first binding site specifically binding to a first antigen and a second binding site specifically binding to a second antigen, to said first and said second antigen, wherein the method comprises the steps of capturing the antibody on a solid phase using a capture reagent specifically binding to a constant domain of the antibody, incubating the captured antibody with the first or the second antigen to form a captured antibody-antigen complex and determining a first binding signal, either i) incubating the captured antibody-antigen complex with the antigen not used for the formation of the captured antibody-antigen complex to form a captured antibody-antigen-antigen complex and determining a second binding signal, or ii) regenerating the surface, capturing the antibody on a solid phase using a capture reagent specifically binding to a constant domain of the antibody, incubating the captured antibody with the antigen not used for the formation of the captured antibody-antigen complex in step b) to form a captured antibody-antigen-antigen complex and determining a third binding signal, and determining the overall or individual binding of the antibody to the first and the second antigen from the first binding signal and the second or third binding signal.

    SOLID PHASE CARRIER, LIGAND-BOUND SOLID PHASE CARRIER, METHOD FOR DETECTING OR SEPARATING TARGET SUBSTANCE, AND METHOD FOR PRODUCING SOLID PHASE CARRIER
    8.
    发明申请
    SOLID PHASE CARRIER, LIGAND-BOUND SOLID PHASE CARRIER, METHOD FOR DETECTING OR SEPARATING TARGET SUBSTANCE, AND METHOD FOR PRODUCING SOLID PHASE CARRIER 审中-公开

    公开(公告)号：US20170292947A1

    公开(公告)日：2017-10-12

    申请号：US15509684

    申请日：2015-09-07

    申请人： JSR CORPORATION ,  JSR Life Sciences Corporation

    发明人： Yuuichi UEYA

    IPC分类号： G01N33/547 ,  C08F293/00 ,  G01N33/543 ,  C08F257/02 ,  C08L43/02

    CPC分类号： G01N33/547 ,  C08F257/02 ,  C08F293/00 ,  C08F293/005 ,  C08F2438/01 ,  C08L43/02 ,  G01N33/54326 ,  G01N33/54393

    摘要： Provided is a solid phase carrier which has high water dispersibility, allows facilitated binding of a ligand to a reactive functional group, and exhibits suppressed non-specific adsorption, and with which, in the case of using the solid phase carrier by having a ligand bound thereto, for example, detection of a target substance can be carried out with high sensitivity and low noise. Disclosed is a solid phase carrier having bound thereto a polymer including a structural unit represented by the following Formula (1) and a structural unit represented by the following Formula (2): wherein in Formula (1), R1 represents a hydrogen atom or a methyl group; and R2 represents an organic group having a zwitterionic structure, in Formula (2), R3 represents a hydrogen atom or a methyl group R4 represents —(C═O)—O—*, —(C═O)—NR6—* (wherein R6 represents a hydrogen atom or a methyl group; and the symbol * represents a position of bonding to R5 in Formula (2)), or a phenylene group; in a case in which R4 represents —(C═O)—O—*, R5 represents a hydrogen atom, or an organic group having a reactive functional group, and in a case in which R4 represents —(C═O)—NR6—* or a phenylene group, R5 represents an organic group having a reactive functional group, provided that R5 is not an organic group having a zwitterionic structure.

    Mutant ROS expression in human cancer
    9.
    发明授权
    Mutant ROS expression in human cancer 有权
    突变型ROS在人类癌症中的表达

    公开(公告)号：US09364477B2

    公开(公告)日：2016-06-14

    申请号：US13146705

    申请日：2010-02-12

    申请人： Ting-Lei Gu ,  Meghan Ann Tucker ,  Herbert Haack ,  Katherine Eleanor Crosby ,  Victoria McGuinness Rimkunas

    发明人： Ting-Lei Gu ,  Meghan Ann Tucker ,  Herbert Haack ,  Katherine Eleanor Crosby ,  Victoria McGuinness Rimkunas

    IPC分类号： C12Q1/68 ,  C07H21/02 ,  C07H21/04 ,  A61K31/506 ,  G01N33/574 ,  G01N33/547

    CPC分类号： A61K31/506 ,  A61K31/4545 ,  C12Q1/6827 ,  C12Q1/6858 ,  C12Q1/6869 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57438 ,  G01N33/57484 ,  G01N2333/9121 ,  G01N2800/52

    摘要： The invention provides the identification of the presence of mutant ROS protein in human cancer. In some embodiments, the mutant ROS are FIG-ROS fusion proteins comprising part of the FIG protein fused to the kinase domain of the ROS kinase. In some embodiments, the mutant ROS is the overexpression of wild-type ROS in cancerous tissues (or tissues suspected of being cancerous) where, in normal tissue of that same tissue type, ROS is not expressed or is expressed at lower levels. The mutant ROS proteins of the invention are anticipated to drive the proliferation and survival of a subgroup of human cancers, particularly in cancers of the liver (including bile duct), pancreas, kidney, and testes. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS polypeptides (e.g., a FIG-ROS(S) fusion polypeptide), probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The identification of the mutant ROS polypeptides enables new methods for determining the presence of these mutant ROS polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

    摘要翻译： 本发明提供了人类癌症中突变型ROS蛋白的存在的鉴定。 在一些实施方案中，突变体ROS是包含与ROS激酶的激酶结构域融合的FIG蛋白的部分的FIG-ROS融合蛋白。 在一些实施方案中，突变体ROS是野生型ROS在癌组织（或怀疑是癌性的组织）中的过表达，其中在相同组织类型的正常组织中ROS不被表达或以较低水平表达。 预期本发明的突变体ROS蛋白质可以驱动人类癌症亚群的增殖和存活，特别是在肝脏（包括胆管），胰腺，肾脏和睾丸癌。 因此，本发明部分地提供了分离的多核苷酸和编码所公开的突变型ROS多肽的载体（例如，FIG-ROS（S）融合多肽），用于检测其的探针，分离的突变多肽，重组多肽和用于检测融合的试剂 和截短的多肽。 鉴定突变体ROS多肽使得能够确定生物样品中这些突变型ROS多肽的存在的新方法，用于筛选抑制蛋白质的化合物的方法，以及抑制以突变多核苷酸或多肽为特征的癌症进展的方法 ，其也由本发明提供。